MarketScreener Strategies Exelixis, Inc.
Equities
EXEL
US30161Q1040
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.92 USD | +2.86% |
|
+0.05% | +0.21% |
| 12/02 | Biogen Inc. Announces Board Changes | CI |
| 11/02 | RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating | MT |
MarketScreener Strategies
Search
 | Exelixis, Inc. : The cure to cancer? | August 05, 2025 at 07:19 pm IST |
 | Exelixis Q1 25 results boost stock and target price | June 25, 2025 at 01:31 pm IST |
 | Exelixis, Inc. : The most promising biotech firm in the US? | February 08, 2019 at 08:28 pm IST |
No results for this search
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition